(Re)solving atherosclerosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Engineered immune-driven theranostics for clinical cardiology.Military Medical Research · 2025
   Review
2. Annexin A1 binds PDZ and LIM domain 7 to inhibit adipogenesis and prevent obesity.Signal transduction and targeted therapy · 2024
   Article
3. Annexin Animal Models-From Fundamental Principles to Translational Research.International journal of molecular sciences · 2021
   Review
4. Annexins in Adipose Tissue: Novel Players in Obesity.International journal of molecular sciences · 2019
   Review
5. Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis.ACS nano · 2016
   Article
6. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.Chemical reviews · 2016
   Review

Corrections and comments

• Comment on
  Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as